Recently, several reports (prevalently microRNA studies) have indicated that the elevated expression of RUNX2 [38,39,40,41] or SOX9 [42,43,44,45,46] conferred resistance to taxanes (prevalently docetaxel) [38,40,41,42] and CDDP [39,43,44,45,46] in prostate [38,41,42], gastric [43,45], lung [39,46], breast [40], and ovarian [44] cancer cells and tissues. Here, SOX9 is linked to cancer.